NCT05895500View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

CompletedOBSERVATIONAL

Enrollment

103

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions

Dry EyeAsthenopia

Interventions

DRUG

Injection for SC administration (120mg/syringe)

Injection

DRUG

Tablet (50mg/tablet), oral

Tablet

Trial Locations (1)

90505

NVision-EWEI-Torrance, Torrance

All Listed Sponsors

lead

Nvision Laser Eye Centers

INDUSTRY

NCT05895500 - Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia | Biotech Hunter | Biotech Hunter